NewsPBS NewsHourMay 18, 2026United States
Supreme Court Upholds Medicare Drug Price Negotiations
The Supreme Court has declined to hear appeals from pharmaceutical companies challenging the government's authority to negotiate drug prices. This decision allows the Medicare price negotiation program established under the 2022 Inflation Reduction Act to continue.
Read the full story at PBS NewsHourWhy It Matters
This ruling ensures that the government can continue efforts to lower prescription drug costs for Medicare beneficiaries.
Key Facts
- The Supreme Court rejected appeals from drug manufacturers regarding Medicare price negotiations.
- The negotiation program was established by the 2022 Inflation Reduction Act.
- The law allows the federal government to directly negotiate drug prices for Medicare.